The Investment Column: Protherics
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.WHEN PROTEUS and Therapeutic Antibodies, the biotechnology tiddlers, merged to form Protherics, the companies said it was to combine the long- term pipeline of one with the short-term revenue stream of the other. Oddly, the company now says it might need more cash and is on the prowl in the UK biotechnology sector.
Perhaps more oddly, this fresh predatory stance comes just as Protherics clinched a rather tasty deal with Eli Lilly, the US pharmaceuticals giant, to license its molecular design technology to develop drugs which limit blood clotting. That's a huge market, and Eli Lilly's last such deal netted $30m (pounds 19m) for for Xenova, another UK biotech.
Protherics would say only that the deal could generate licence fees of at least $5m. Eli Lilly has gagged Protherics on the financials of the deal, but the total package, including royalities, should add up to between $25m and $40m. Investors should in any case take heart that a company such as Eli Lilly has at last endorsed a Protherics product.
Elsewhere, there's less excitement in the portfolio. The group's rattlesnake bite treatment is still facing regulatory hurdles and will not be on the market ahead of the summer, when rattlesnakes come out to play. The shares barely moved on yesterday's results, which came in bang in line with forecasts. The news the group is looking for more deals is no sign of weakness now Eli Lilly has given its stamp of approval. The shares, at 45.5p, are worth a punt.
Edited by Chris Hughes
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments